Perioperative ketorolac in high risk breast cancer patients. Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial

Medical Hypotheses

Volumn 81, Issue 4, 2013, Pages 707-712

  Forget, Patrice ^a   Berlière, Martine ^a   van Maanen, Aline ^a   Duhoux, Francois P ^a   Machiels, Jean Pascal ^a   Coulie, Pierre G ^b   Bouche, Gauthier ^c   De Kock, Marc ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b DE DUVE INSTITUTE   (Belgium)

^c NONE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

KETOROLAC; KETOROLAC TROMETAMOL; PLACEBO;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOMA IN SITU; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GOLD STANDARD; HIGH RISK PATIENT; HUMAN; KIDNEY DISEASE; LUNG DISEASE; METHODOLOGY; OPERATIVE BLOOD LOSS; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; POSTOPERATIVE ANALGESIA; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PAIN; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TUMOR INVASION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BREAST NEOPLASMS; FEMALE; HUMANS; INFLAMMATION; KETOROLAC; PATIENT SELECTION; PERIOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAMPLE SIZE;

EID: 84883765692     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.07.033     Document Type: Article

References (31)

1. Forget P., Machiels J.-P., Coulie P.G., Berliere M., Poncelet A.J., Tombal B., et al. Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung and kidney cancer surgery. Ann Surg Oncol 2013, [Epub ahead of print].
2. Hung H.Y., Chen J.S., Yeh C.Y., Changchien C.R., Tang R., Hsieh P.S., et al. Effect of preoperative neutrophil-lymphocyte ratio on the surgical outcomes of stage II colon cancer patients who do not receive adjuvant chemotherapy. Int J Colorectal Dis 2011, 26(8):1059-1065.
3. Tomita M., Shimizu T., Ayabe T., Yonei A., Onitsuka T. Preoperative neutrophil to lymphocyte ratio as a prognostic predictor after curative resection for non-small cell lung cancer. Anticancer Res 2011, 31(9):2995-2998.
4. Sharaiha R.Z., Halazun K.J., Mirza F., Port J.L., Lee P.C., Neugut A.I., et al. Elevated preoperative neutrophil:lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann Surg Oncol 2011, 18(12):3362-3369.
5. Kim H.S., Han K.H., Chung H.H., Kim J.W., Park N.H., Song Y.S., et al. Neutrophil to lymphocyte ratio for preoperative diagnosis of uterine sarcomas: a case-matched comparison. Eur J Surg Oncol 2010, 36(7):691-698.
6. Garcea G., Ladwa N., Neal C.P., Metcalfe M.S., Dennison A.R., Berry D.P. Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma. World J Surg 2011, 35(4):868-872.
7. Azab B., Bhatt V.R., Phookan J., Murukutla S., Kohn N., Terjanian T., et al. Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol 2012, 19(1):217-224.
8. Keizman D., Ish-Shalom M., Huang P., Eisenberger M.A., Pili R., Hammers H., et al. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer 2012, 48(2):202-208.
9. Proctor M.J., Morrison D.S., Talwar D., Balmer S.M., Fletcher C.D., O'Reilly D.S., et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow inflammation outcome study. Eur J Cancer 2011, 47(17):2633-2641.
10. Forget P., Vandenhende J., Berliere M., Machiels J.P., Nussbaum B., Legrand C., et al. Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis. Anesth Analg 2010, 110(6):1630-1635.
11. Burn J., Gerdes A.M., Macrae F., Mecklin J.P., Moeslein G., Olschwang S., et al. CAPP2 investigators. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2012, 378(9809):2081-2087.
12. Rothwell P.M., Fowkes F.G., Belch J.F., Ogawa H., Warlow C.P., Meade T.W. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011, 377(9759):31-41.
13. Rothwell P.M., Wilson M., Price J.F., Belch J.F., Meade T.W., Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012, 379(9826):1591-1601.
14. Rothwell P.M., Price J.F., Fowkes F.G., Zanchetti A., Roncaglioni M.C., Tognoni G., et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012, 379(9826):1602-1612.
15. Demaria S., Pikarsky E., Karin M., Coussens L.M., Chen Y.C., El-Omar E.M., et al. Cancer and inflammation: promise for biologic therapy. J Immunother 2010, 33(4):335-351.
16. Retsky M.W., Demicheli R., Hrushesky W.J., Baum M., Gukas I.D. Dormancy and surgery-driven escape from dormancy help explain some clinical features of breast cancer. APMIS 2008, 116(7-8):730-741.
17. Jatoi I., Tsimelzon A., Weiss H., Clark G.M., Hilsenbeck S.G. Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Res Treat 2005, 89(2):173-178.
18. Hilsenbeck S.G., Ravdin P.M., de Moor C.A., Chamness G.C., Osborne C.K., Clark G.M. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 1998, 52(1-3):227-237.
19. Baum M., Demicheli R., Hrushesky W., Retsky M. Does surgery unfavourably perturb the natural history of early breast cancer by accelerating the appearance of distant metastases?. Eur J Cancer 2005, 41(4):508-515.
20. Mansell J., Monypenny I.J., Skene A.I., Abram P., Carpenter R., Gattuso J.M., et al. Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat 2009, 117(1):91-98.
21. Retsky M., Rogers R., Demicheli R., Hrushesky W.J.M., Gukas I., Vaidya J.S., et al. NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup. Breast Cancer Res Treat 2012, 134(2):881-888.
22. Sessler D., Ben-Eliyahu S., Mascha E.J., Parat M.O., Buggy D.J. Can regional analgesia reduce the risk of recurrence after breast cancer? Methodology of a multicenter randomized trial. Contem Clin Trials 2008, 29:517-526.
23. Mandrekar S.J., Qi Y., Hillman S.L., Allen Ziegler K.L., Reuter N.F., Rowland K.M., et al. Endpoints in phase II trials for advanced non-small cell lung cancer. J Thorac Oncol 2010, 5(1):3-9.
24. American Society of Anesthesiologists Task Force on Acute Pain Management Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. Anesthesiology 2012, 116(2):248-273.
25. De Oliveira G.S., Agarwal D., Benzon H.T. Perioperative single dose ketorolac to prevent postoperative pain. A meta-analysis of randomized trials. Anesth Analg 2012, 114(2):424-433.
26. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
27. Hussain M., Javeed A., Ashraf M., Al-Zaubai N., Stewart A., Mukhtar M.M. Non-steroidal anti-inflammatory drugs, tumour immunity and immunotherapy. Pharmacol Res 2012, 66(1):7-18.
28. Forget P., Collet V., Lavand'homme P., De Kock M. Does analgesia and condition influence immunity after surgery? Effects of fentanyl, ketamine and clonidine on natural killer activity at different ages. Eur J Anaesthesiol 2010, 27(3):233-240.
29. Forget P., De Kock M. Could anaesthesia, analgesia and sympathetic modulation affect neoplasic recurrence after surgery? A systematic review centred over the modulation of natural killer cells activity. Ann Fr Anesth Reanim 2009, 28(9):751-768.
30. Shakhar G., Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients?. Ann Surg Oncol 2003, 10(8):972-992.
31. Forget P., Coulie P.G., Retsky M., Demicheli R., Machiels J.P., De Kock M. Is there a rationale for an anesthesiologist's role against cancer recurrence?. Acta Anaesthesiol Belg 2013, 64(1):15-24.